Stoke Therapeutics’ (STOK) Buy Rating Reaffirmed at Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $22.00 price objective on the stock. Needham & Company LLC’s target price points to a potential upside of 272.88% from the company’s previous close.

Several other brokerages have also issued reports on STOK. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Chardan Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Buy” and a consensus price target of $24.67.

Stoke Therapeutics Stock Down 1.8 %

Shares of STOK opened at $5.90 on Wednesday. The company has a market capitalization of $319.06 million, a price-to-earnings ratio of -2.81 and a beta of 1.09. Stoke Therapeutics has a 52-week low of $5.45 and a 52-week high of $17.58. The stock has a 50 day moving average price of $8.68 and a 200 day moving average price of $10.68.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities analysts anticipate that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock worth $143,332 in the last quarter. Company insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in STOK. GAMMA Investing LLC lifted its position in shares of Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock valued at $36,000 after acquiring an additional 5,084 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Stoke Therapeutics in the 4th quarter valued at approximately $63,000. Teacher Retirement System of Texas acquired a new position in Stoke Therapeutics during the fourth quarter worth $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in Stoke Therapeutics during the fourth quarter worth $124,000. Finally, Tower Research Capital LLC TRC grew its stake in Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after acquiring an additional 4,918 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.